Clinical and laboratory features of 91 patients with MMM who underwent LT
Patient characteristics . | Data . |
|---|---|
| Sex, no. (%) | |
| Male | 55 (60) |
| Female | 36 (40) |
| Median age, y (range) | |
| At diagnosis of MMM | 63 (21-81) |
| At time of LT | 66 (41-82) |
| Type of MMM, no. (%) | |
| Agnogenic myeloid metaplasia | 49 (54) |
| Postpolycythemic myeloid metaplasia | 22 (24) |
| Postthrombocythemic myeloid metaplasia | 20 (22) |
| Lille10 prognostic score at diagnosis of MMM, available in 48 patients, no. (%) | |
| 0 | 26 (54) |
| 1 | 18 (38) |
| 2 | 4 (8) |
| Circulating blasts present at time of MMM diagnosis, available in 48 patients, no. (%) | 23 (48) |
| Median interval between diagnosis of MMM and LT, mos (range) | 31 (2-441) |
| Prior treatment for MMM, no. (%) | |
| Hydroxyurea | 47 (52) |
| Splenectomy | 33 (36) |
| Radioactive phosphorus, P32 | 12 (13) |
| Alkylators such as busulfan, cyclophosphamide, etc | 12 (13) |
Patient characteristics . | Data . |
|---|---|
| Sex, no. (%) | |
| Male | 55 (60) |
| Female | 36 (40) |
| Median age, y (range) | |
| At diagnosis of MMM | 63 (21-81) |
| At time of LT | 66 (41-82) |
| Type of MMM, no. (%) | |
| Agnogenic myeloid metaplasia | 49 (54) |
| Postpolycythemic myeloid metaplasia | 22 (24) |
| Postthrombocythemic myeloid metaplasia | 20 (22) |
| Lille10 prognostic score at diagnosis of MMM, available in 48 patients, no. (%) | |
| 0 | 26 (54) |
| 1 | 18 (38) |
| 2 | 4 (8) |
| Circulating blasts present at time of MMM diagnosis, available in 48 patients, no. (%) | 23 (48) |
| Median interval between diagnosis of MMM and LT, mos (range) | 31 (2-441) |
| Prior treatment for MMM, no. (%) | |
| Hydroxyurea | 47 (52) |
| Splenectomy | 33 (36) |
| Radioactive phosphorus, P32 | 12 (13) |
| Alkylators such as busulfan, cyclophosphamide, etc | 12 (13) |